NICE, FRANCE--(Marketwired - April 17, 2015) - Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, researchers presented one-year ...

In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

January 21, 2010 (Silver Spring, Maryland) — Thoratec's HeartMate II is the first continuous-flow left-ventricular assist device (LVAD) approved by the FDA for transplant-ineligible heart-failure ...

Washington, DC - Data from 64 HeartMate II (Thoratec) left ventricular assist device (LVAD) patients treated at the Henry Ford Hospital in Detroit suggest that many of the patients implanted with the ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

MONTREAL, QB--(Marketwired - April 25, 2013) - Today, researchers will reveal the latest findings on a post-approval study for destination therapy (DT) at the International Society for Heart and Lung ...

Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump as a key factor in boosting 2012 first-quarter revenue 27% versus a year earlier. As ...

The FDA Circulatory System Devices Advisory Panel voted to recommend, with conditions, approval of the HeartMate II left ventricular assist system. The HeartMate II (Thoratec) is an LV pump designed ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...

Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine ...

NEW ORLEANS, LA—Final, full results from the MOMENTUM 3 trial show that the HeartMate 3 magnetically levitated, centrifugal-flow left ventricular assist device (LVAD) is superior to the ...